Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in transfusion-dependent low/intermediate-1 risk MDS and low-risk CMML
2009-011483-11Phase 2Completed
- Sponsor
- Nordic MDS Group
- Start
- Sep 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Nordic MDS Group. Primary endpoints: Effect of treatment on haemoglobin level at week 28 and Transfusion independence over 24 weeks. Started Sep 2009; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2009-011483-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011483-11.